All In Biotech

Drug Trial Radar · NCT04619797

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreated Advanced Non-Squamous Non-Small-Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Jun 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 542 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

542

Actual

Start

Dec 15, 2020

Primary completion

Apr 19, 2024

Study completion Nov 20, 2025

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tiragolumab in combination with atezolizumab plus pemetrexed and carboplatin/cisplatin (Arm A) compared with placebo in combination with pembrolizumab plus pemetrexed and carboplatin/cisplatin (Arm B) in participants with previously untreated, locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). Eligible participants will be randomized in a 1:1 ratio to receive one of the following treatment regimens during the induction phase: * Arm A: Tiragolumab plus atezolizumab plus pemetrexed and carboplatin or cisplatin * Arm B: Placebo plus pembrolizumab plus pemetrexed and carboplatin or cisplatin Following the induction phase, participants will continue maintenance therapy with either tiragolumab in combination with atezolizumab and pemetrexed (Arm A) or placebo in combination with pembrolizumab and pemetrexed (Arm B).

Conditions

  • Non-small Cell Lung Cancer (NSCLC)

Interventions

  • TiragolumabDrug

    Tiragolumab at a fixed dose of 600 milligrams (mg), administered by intravenous (IV) infusion, every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

  • AtezolizumabDrug

    Atezolizumab at a fixed dose of 1200 mg, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

  • PemetrexedDrug

    Pemetrexed 500 milligrams per square meter (mg/m\^2), administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

  • CarboplatinDrug

    Carboplatin at dose of area under the concentration-time curve (AUC) of 5, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.

  • CisplatinDrug

    Cisplatin 75 mg/m\^2, administered by IV infusion, Q3W on Day 1 of each 21-day cycle for 4 cycles.

  • Tiragolumab Matching PlaceboDrug

    Matching placebo, administered by IV infusion, Q3W on Day 1 of each 21-day cycle.

  • PembrolizumabDrug

    Pembrolizumab at a fixed dose of 200 mg, administered by IV infusion, Q3W, on Day 1 of each 21-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) as Determined by the InvestigatorTime frame: From randomization to first occurrence of PD or death from any cause (up to approximately 40 months)
  2. Overall Survival (OS)Time frame: From randomization to death from any cause (up to approximately 40 months)

Locations

127 sites in 21 countries. Site status is shown where the registry gives one.

  • UCLA

    Los Angeles, California

  • PIH Health Whittier Hospital

    Whittier, California

  • SCRI Florida Cancer Specialists South

    Fort Myers, Florida

  • SCRI Florida Cancer Specialists North

    St. Petersburg, Florida

  • Advent Health Orlando

    Winter Park, Florida

  • Northwest Georgia Oncology Centers PC - Marietta

    Marietta, Georgia

  • Fort Wayne Medical Oncology and Hematology, Inc

    Fort Wayne, Indiana

  • Baptist Health Lexington

    Lexington, Kentucky

  • Tennessee Oncology Chattanooga

    Chattanooga, Tennessee

  • Sarah Cannon Research Institute / Tennessee Oncology

    Nashville, Tennessee

  • Inova Schar Cancer Institute

    Fairfax, Virginia

  • AZORG Campus Aalst-Moorselbaan

    Aalst, Belgium

  • Cliniques Universitaires St-Luc

    Brussels, Belgium

  • CHU UCL Mont-Godinne

    Mont-godinne, Belgium

  • Vitaz

    Sint-Niklaas, Belgium

  • Crio - Centro Regional Integrado de Oncologia

    Fortaleza, Ceará, Brazil

  • Oncocentro Belo Horizonte

    Belo Horizonte, Minas Gerais, Brazil

  • Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda

    Ijuí, Rio Grande do Sul, Brazil

  • Hospital das Clinicas - UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Nossa Senhora da Conceicao

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Cancer de Barretos

    Barretos, São Paulo, Brazil

  • Instituto do Cancer do Estado de Sao Paulo - ICESP

    São Paulo, São Paulo, Brazil

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

  • Royal Victoria Regional Health Centre

    Barrie, Ontario, Canada

  • Lakeridge Health Oshawa

    Oshawa, Ontario, Canada

  • Sault Area Hospital

    Sault Ste. Marie, Ontario, Canada

  • Beijing Cancer Hospital

    Beijing, China

  • Jilin Cancer Hospital

    Changchun, China

  • Xiangya Hospital Central South University

    Changsha, China

  • Affiliated Hospital of Chengde Medical University

    Chengde, China

  • Sichuan Cancer Hospital

    Chengdu, China

  • West China Hospital - Sichuan University

    Chengdu, China

  • Anhui Provincial Hospital

    Hefei, China

  • Jinan Central Hospital

    Jinan, China

  • Pingxiang People's Hospital

    Pingxiang, China

  • Qingdao Central Hospital

    Qingdao, China

  • Weifang People's Hospital

    Weifang, China

  • Hubei Cancer Hospital

    Wuhan, China

  • The First Affiliated Hospital of Xian Jiao Tong University

    Xi'an, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, China

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.